Siddharth Singh
Gastroenterology · Scottsdale, AZNPI 1508023227
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,948 of the $31,991 with a category attached, or 71.7%. Pfizer accounts for 99.3% of it on its own, with 2 other manufacturers making up the rest. Among gastroenterology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $2665.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$32K
- Takeda Pharmaceuticals U.S.A., Inc.$202
- Bristol Myers Squibb$19
Across 49 payments — averaging $13,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$342K
- AbbVie$208K
- Janssen Research & Development, LLC$91K
- Genentech, Inc.$31K
- Gilead$12K
- Takeda Pharmaceuticals U.S.A., Inc.$186
What the payments were for
- Consulting fees$8,00125%
- Speaking & faculty fees$22,94872%
- Travel & lodging$9693%
- Food & beverage$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 7 | $31,770 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $202 |
| Bristol Myers Squibb | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Entyvio$125
How this compares
$31,991 in reported general payments places this provider in the 90th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 76 | $1,983,335 |
| GattexTeduglutide | 26 | $1,206,830 |
| Skyrizi On-BodyRisankizumab-Rzaa | 26 | $485,401 |
| Humira(Cf) PenAdalimumab | 14 | $134,004 |
| RemicadeInfliximab | 14 | $95,539 |
| Entyvio PenVedolizumab | 15 | $84,303 |
| Mesalamine | 44 | $29,244 |
| Opium Tincture | 12 | $2,674 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 35 | $2,102 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $1,465 |
| Sodium Chloride | 45 | $989 |
| Budesonide DrBudesonide | 13 | $925 |
| Omeprazole | 30 | $429 |
| LoperamideLoperamide Hcl | 11 | $403 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $202 | $1,206,83026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Scottsdale
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
- Woong KimScottsdale$138K
- Adam HarrisScottsdale$127K
- Anil SeetharamScottsdale$111K
- Amar ThosaniScottsdale$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.